Studies biomarkers and outcomes in lung or breast cancer patients
Observes patients with lung or breast cancer, linking biomarkers to their outcomes.
Plain-language title generated from the registry record
Registry title: Copenhagen Master Observational Trial
Key facts
- Where
- Copenhagen, DenmarkSee the site
Where in Denmark
- RigshospitaletCopenhagen, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Copenhagen University Hospital, Rigshospitalet
- Trial code
- NCT05145244
- Record updated
- 12 August 2026
- Original description
The primary objectives of this prospective non-interventional study (NIS) are to assess and describe outcomes in relation to biomarkers, including whole-genome sequencing (WGS) in patients with non- small cell lung cancer (NSCLC) or breast cancer receiving treatment offered in the clinic (standard of care or included in clinical trials).Read full original descriptionShow less
Copenhagen Master Observational Trial (C-MOT): A Prospective Investigator-initiated Observational Study to Study Biomarkers in Relation to Clinical Outcome in Patients With Non-Small Cell Lung Cancer or Breast Cancer
The primary objectives of this prospective non-interventional study (NIS) are to assess and describe outcomes in relation to biomarkers, including whole-genome sequencing (WGS) in patients with non- small cell lung cancer (NSCLC) or breast cancer receiving treatment offered in the clinic (standard of care or included in clinical trials).
Inclusion: Patients (≥ 18 years of age) with diagnosis of NSCLC or breast cancer amenable to medical or radiation therapy with curative or palliative intent; Evidence of a personally signed and dated informed consent form document indicating that the patient has been informed of all pertinent aspects of the study; Able to read and understand Danish; Willing and able to complete collection of data including WGS.
Exclusion: Patient with breast cancer initiating adjuvant systemic therapy; In the judgment of the investigator, the patient's life expectancy is fewer than 3 months at the time of diagnosis of NSCLC or breast cancer.